Axsome Therapeutics, Inc. AXSM

Key data

The business

Axsome is a central-nervous-system drugmaker with three products on pharmacy shelves and one engine. That engine is Auvelity, an oral pill combining dextromethorphan and bupropion, approved in 2022 for major depression. Unlike the SSRIs it competes with, it works within a week rather than a month, and it drives every number here. The dextromethorphan blocks the NMDA glutamate receptor and acts on the sigma-1 receptor, while the bupropion mainly stops the liver from clearing the dextromethorphan too fast, keeping blood levels high enough to act. The pivotal was the GEMINI Phase 3 trial (NCT04019704), published in the Journal of Clinical Psychiatry in 2022. Alongside it sit Sunosi (solriamfetol), a wakefulness drug bought from Jazz for daytime sleepiness, and Symbravo, a meloxicam-and-rizatriptan migraine tablet launched in 2025. The moat is patent-protected drug combinations plus a specialty psychiatry salesforce that is costly to rebuild. What the patient holds is a once-daily tablet a psychiatrist reaches for when an SSRI has failed and time matters.

The numbers

Five quarters show a business compounding fast and still bleeding.

*Derived from the annual filing less the three filed nine-month figures.

Revenue climbed from $150 million to $218 million in a year, up 46% on the latest quarter, with Auvelity the bulk of it and Symbravo adding a new line. The loss is noisier. Q4 2025 narrowed to $29 million as revenue jumped, then Q1 2026 blew back out to $65 million on the usual first-quarter reset in drug rebates, before settling at $51 million. Every one of the last four quarters lost more than analysts modeled, a streak that matters because the whole case rests on when the losses stop.

Zoom out and the arc is cleaner: $50 million of revenue in 2022 to $638 million in 2025, powered by Auvelity's ramp and the Symbravo launch, while the annual loss actually shrank in 2025 for the first time. Trailing sales are about $776 million, and the company holds $320 million of cash as of June 30, 2026. This is not a pre-revenue biotech living on a cash runway. It is a commercial company two years from the profit consensus pencils in for 2028, $12.56 a share, rising to $22.27 by 2029. The variant the market may be under-crediting: at 13.6 times sales with 46% growth, the price barely pays for the three drugs already selling, let alone the pipeline. What settles it is whether quarterly revenue holds above 40% growth while the loss narrows on schedule. A quarter that grows slower and loses more would break it.

The pipeline is where the free option sits.

Management

Herriot Tabuteau, the founder and chief executive, still runs the company he built, and the record from his own wallet points one way: zero insider purchases over the last year against $111 million of sales across 29 transactions, with Tabuteau himself selling more than $37 million in three lots between January and July 2026. Plan status is not disclosed in the filings I can see, so I cannot tell you how much was pre-scheduled 10b5-1 selling versus discretionary, and that distinction is the whole meaning of the number. The other tell is dilution. The share count has grown from about 38 million in 2021 to 52 million now, roughly 37% more owners, the price of funding losses without a partner.

How it fails or surprises you

Auvelity concentration and net-price erosion. One drug carries the company, and the 2022 IRA Part D redesign now forces manufacturer discounts of 10% in the initial coverage phase and 20% in catastrophic, on top of normal rebates. If Auvelity's net price compresses as volume shifts into those phases, 46% top-line growth converts into far less profit, and the 2028 math breaks.

The four-quarter miss streak. Revenue compounds, yet every quarter since late 2025 has lost more than the Street modeled, most starkly Q1 2026 at a $1.26 loss versus $0.85 expected. The read says breakeven arrives around 2027-2028. The one fact it explains least is why losses keep widening against estimates. If that continues, the forward multiple is priced on air.

AXS-12 and the franchise (right tail). A narcolepsy drug, AXS-12, carries a PDUFA date of May 1, 2027, and solriamfetol is in Phase 3 for binge eating and shift-work disorder. Approve one or two and Axsome becomes a five-drug CNS house. At 13.6 times sales the market pays for none of that today. The first tell is the May 2027 decision.

Closing thoughts

No single quarter settles this, and no single readout either. What matters is a trajectory. The evidence points to a company that reaches profitability if Auvelity keeps compounding and the newer drugs land, and stalls if net pricing erodes or breakeven keeps sliding right. Watch the revenue growth rate against the loss each quarter, with the AXS-12 decision in May 2027 as the discrete catalyst. I judge the right tail the fatter one: 46% growth, a PEG near 0.2, and a pipeline the multiple ignores outweigh the downside, though the persistent misses are a genuine warning and the founder's steady selling is not nothing. What is at risk if the downside linchpin breaks is the 2028 profit date. What the upside is worth is a multi-drug franchise re-rated well above 13.6 times sales.

The bet is still that Auvelity keeps winning patients from older SSRIs, and that a migraine tablet and a coming narcolepsy drug turn one product into a family. It breaks if revenue growth drops below 40% while the quarterly loss fails to narrow. Those two numbers, side by side each quarter, tell you first whether the 2028 profit is real or receding.